Nicolas Maignan is Chief Operating Officer at Kantify, a biotechnology company developing artificial intelligence methods for small-molecule drug discovery. He holds an engineering degree from the French National Polytechnic Institute and has ten years of experience in machine learning. His research focuses on the application of AI models to target identification, small-molecule–protein interaction prediction, and ADMETox assessment. He has contributed to drug discovery programs in oncology, neuromuscular disorders, ion channel pharmacology, and drug repositioning, with an emphasis on integrating computational methods with experimental and translational research.